Analysis of bcl-2 in sporadic breast carcinoma

Cancer

Volumn 80, Issue 11, 1997, Pages 2100-2108

  Dueñas González, Alfonso ^a   Abad Hernández, María Del Mar ^a   Cruz Hernández, Juan Jesús ^a   González Sarmiento, Rogelio ^a,b  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Bcl 2; Breast carcinoma; CpG island; Gene mutation; Loss of heterozygosity; Medical oncology; Methylation; P53

Indexed keywords

DNA; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CLINICAL ARTICLE; DNA METHYLATION; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 1842413726     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971201)80:11<2100::aid-cncr9>3.0.co;2-%23     Document Type: Article

References (45)

1. Wyllie AH. The genetic regulation of apoptosis. Curr Opin Genet Dev 1995;5:97-104.
2. Tsujimoto Y, Bashir MM, Givol I, Cossman J, Jaffe E, Croce CM. DNA rearrangements in human follicular lymphoma can involve the 5′ or the 3′ region of the bcl-2 gene. Proc Natl Acad Sci USA 1987;84:1329-31.
3. Seto M, Jaeger V, Hockett R, Graninger W, Bennett S, Goldman P, et al. Alternative promoters and exons, somatic mutation and deregulation of Bcl-2-Ig fusion gene in lymphoma. EMBO J 1988;7:123-31.
4. McDonnell T, Troncoso P, Brisbary S, Logothetis C, Chung I, Hsieh J, et al. Expression of the protooncogene BCL-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-4.
5. Pezzella F, Turley H, Kuzu I, Tungekar M, Dunnil M, Pierce C, et al. BCL-2 protein in non-small cell lung carcinoma. N Engl J Med 1993;329:690-4.
6. Higashiyama M, Doi O, Kodama K, Yogokouchi H, Tateishi R. High prevalence of bcl-2 expression in small cell lung cancer. Anticancer Res 1995;15:503-5.
7. Alderson LM, Castleberg RL, Harsh GR, Louis DN, Henson JW. Human gliomas with wild-type p53 express bcl-2. Cancer Res 1995;55:999-1001.
8. Lu QL, Elia G, Lucas S, Thomas JA. BCL-2 protooncogene expression in Epstein-Barr virus associated nasopharyngeal carcinoma. Int J Cancer 1993;53:29-35.
9. Lauwers GY, Scott GV, Karpeh MS. Immunohistochemical evaluation of bcl-2 protein expression in gastric adenocarcinomas. Cancer 1995;75:2209-13.
10. Sabourini JC, Martin A, Baruch J, Truc JB, Gompel A, Poitout P. bcl-2 expression in normal breast tissue during the menstrual cycle. Int J Cancer 1994;59:1-6.
11. Nathan B, Gusterson B, Jadajel D, O'Hare M, Anbazhagan R, Jayatilake H, et al. Expression of BCL-2 in primary breast cancer and its correlation with tumor phenotype. Ann Oncol 1994;5:409-14.
12. Johnston SRD, MacLennan KA, Sacks NPM, Salter J, Smith IE, Dowsett M. Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen. Eur J Cancer 1994;30A:1663-9.
13. Sierra A, Lloveras B, Castellsague X, Moreno L, Garcia-Ramirez M, Fabra A. Bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma. Int J Cancer 1995;60:54-60.
14. Bargou RC, Daniel PT, Mapara MY, Bommert K, Wagener C, Kallinich B, et al. Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer 1995;60:854-9.
15. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994;54:2095-7.
16. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994;86:499-504.
17. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 1994;69:135-9.
18. Gorczyca W, Markiewski M, Kram A, Tuziak T, Domagala W. Immunohistochemical analysis of bcl-2 and p53 expression in breast carcinomas: their correlation with Ki-67 growth fraction. Virchows Arch 1995;426:229-33.
19. Hurlimann J, Larrinaga B, Vala DL. bcl-2 protein in invasive ductal breast carcinomas. Virchows Arch 1995;426:163-8.
20. Doglioni C, Dei-Tos AP, Laurino L, Chiarelli C, Barbareschi M, Viale G. The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status. Virchows Arch 1994;424:47-51.
21. Gee JM, Robertson JF, Ellis IO, Willsher P, McClelland RA, Hoyle HB, et al. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 1994;59:619-28.
22. Joensuu H, Pylkkanen L, Toikkanen S. Bcl-2 protein expression and long term survival in breast cancer. Am J Pathol 1994;145:1191-8.
23. Baylin SB, Makos M, Wu J, Chin Yen R-W, de Bustros A, Vertino P, et al. Abnormal pattern of DNA methylation in human neoplasia: potential consequences for tumor progression. Cancer Cells 1991;3:383-90.
24. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54:4855-78.
25. Haffner R, Oren M. Biochemical properties and biological effects of p53. Curr Opin Genet Dev 1995;5:84-90.
26. Chiou SK, Rao L, White E. Bcl-2 blocks p53-dependent apoptosis. Mol Cell Biol 1994;14:2556-63.
27. Miyashita T, Krajweski S, Krajewska M, Wang GH, Lin HK, Liebermann DA, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax expression in vitro and in vivo. Oncogene 1994;9:1799-805.
28. Dunn JM, Hastrich DJ, Newcomb P, Webb JCJ, Maitland NJ, Farndon JR. Correlation between p53 mutations and antibody staining in breast carcinoma. Br J Surg 1993;80:1410-2.
29. MacGeoch C, Barnes DM, Newton JA, Mohammed S, Hodgson SV, Ng M, et al. p53 protein detected by immunohistochemical analysis is not always mutant. Dis Markers 1993;11:239-50.
30. Lohmann D, Ruhri C, Schmitt M, Graeff H, Hofler H. p53 protein as an indicator for p53 gene mutation in breast cancer. Occurrence of false-positives and false-negatives. Diagn Mol Pathol 1993;2:36-41.
31. Dueñas-González A, Cruz-Hernández J, Abad-Hernández MM, Ramos M, González-Sarmiento R. Utilidad de la técnica de PCR-SSCP para la deteccion de mutaciones del gen p53 en cáncer de mama. Med Clin (Barc) 1996;106:721-4.
32. Fisher E, Redmon C, Fisher B. Histologic grading of breast cancer. Pathol Annu 1980;15:239-51.
33. Orfao A, Ciudad J, Gonzalez M, San Miguel JF, Garcia AR, Lopez-Berges MC, et al. Prognostic value of S-phase white blood cell count in B-cell chronic lymphocytic leukemia. Leukemia 1992;6:47-51.
34. Sánchez-García I, Martín-Seisdedos C, Pérez-Grande R, Corral de la Calle J, Rodríguez-Arias C, González-Sarmiento R. Análisis comparativo de dos métodos de extracción de ADN. Sangre (Barc) 1990;35:405-7.
35. Sánchez I, San Miguel JF, Corral J, Martín C, Pérez R, González M, et al. Gene rearrangement in acute non-lymphoblastic leukaemia: correlation with morphological and immunophenotypic characteristics of blast cells. Br J Haematol 1995;89:104-9.
36. Adachi M, Cossman J, Longo D, Croce CM, Tsujimoto Y. Variant translocation of the bcl-2 gene to immunoglobulin light chain gene in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1989;86:2771-4.
37. Cleary ML, Sklar J. Nucleotide sequence of a t(14; 18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 1985;82:7439-43.
38. Cleary ML, Galili N, Sklar J. Detection of a second t(14; 18) breakpoint cluster region in human follicular lymphomas. J Exp Med 1986;164:315-20.
39. Bourn D, Carter SA, Mason S, Gareth D, Evans R, Strachan T. Germline mutations in the neurofibromatosis type 2 tumour suppressor gene. Hum Mol Genet 1994;3:813-6.
40. Ghia P, Dianzani I, Serra A, Rosso C, Caligari-Carpio F. A frequent EcoRI polymorphism in the bcl-2 gene. Hum Genet 1993;91:513.
41. Devilee P, van Vliet M, Kuipers-Dijkshoorn N, Pearson PL, Cornelisse CJ. Somatic genetic changes on chromosome 18 in breast carcinomas: is the DCC gene involved? Oncogene 1991;6:311-5.
42. Nagatake M, Osada H, Kondo M, Uchida K, Nishio M, Shimokata K, et al. Aberrant hypermethylation at the bcl-2 locus at 18q21 in human lung cancers. Cancer Res 1996;56:1886-91.
43. Kovach JS, Hartmann A, Blaszyk H, Cunningham J, Schaid D, Sommer SS. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci USA 1996;93:1093-6.
44. Hartmann A, Blaszyk H, McGovern RM, Schroeder JJ, Cunningham J, De-Vries EM, et al. p53 gene mutations outside of exons 5-8: the patterns differ in breast and other cancers. Oncogene 1995;10:681-8.
45. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994;54:3131-5.